Therapeutic Asset Ratings

183 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Nelmastobart Non-Small Cell Lung Carcinoma	STCube, Inc.	P2	CCC (48)
Rain-32 Non-Small Cell Lung Carcinoma	Rain Oncology Inc	P2	CCC (48)
Vidutolimod Non-Small Cell Lung Carcinoma	Regeneron Pharmaceuticals	P2	CC (46)
azd5305 Non-Small Cell Lung Carcinoma	University of Leeds	P1/2	CC (46)
dzd6008 Non-Small Cell Lung Carcinoma	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	P1/2	CC (46)
Polyiclc Non Small Cell Lung Cancer	Washington University School of Medicine	P1/2	CC (45)
Tovorafenib Non-Small Cell Lung Carcinoma	Day One Biopharmaceuticals, Inc.	P2	CC (44)
Carotuximab Non-Small Cell Lung Carcinoma	Karen Reckamp, MD, MS	P1	CC (44)
Cxcr5 Modified Egfr Chimeric Antigen Receptor Autologous T Cells Non-Small Cell Lung Carcinoma	Sun Yat-sen University	P1	CC (42)
a2b530 Non-Small Cell Lung Carcinoma	A2 Biotherapeutics Inc.	P1/2	CC (41)
Abt-101 Non-Small Cell Lung Carcinoma	Anbogen Therapeutics, Inc.	P1/2	CC (41)
Alintegimod Non-Small Cell Lung Carcinoma	7 Hills Pharma, LLC	P1/2	CC (41)
Bevacizumab-Awwb Non-Small Cell Lung Carcinoma	Criterium, Inc.	P1/2	CC (41)
bi-1910 Non-Small Cell Lung Carcinoma	BioInvent International AB	P1/2	CC (41)
Difluoromethylornithine Non-Small Cell Lung Carcinoma	H. Lee Moffitt Cancer Center and Research Institute	P1/2	CC (41)
Env-501 Non-Small Cell Lung Carcinoma	Hummingbird Bioscience	P1/2	CC (41)
Fmc-376 Non-Small Cell Lung Carcinoma	Frontier Medicines Corporation	P1/2	CC (41)
Gavo-Cel Non-Small Cell Lung Carcinoma	TCR2 Therapeutics	P1/2	CC (41)
Hbi 0201-Eso Tcrt Non-Small Cell Lung Carcinoma	Hadassah Medical Organization	P1/2	CC (41)
ilb2109 Non-Small Cell Lung Carcinoma	Innolake Biopharm	P1/2	CC (41)
immunoglobulin G1-kappa, anti-[Homo sapiens KLRB1 (killer cell lectin like receptor B1, NKR-P1A, natural killer cell surface protein P1A, CLEC5B, CD161)], Homo sapiens monoclonal antibody; gamma1 heavy chain Homo sapiens (1-450) [VH (Homo sapiens IGHV3-2301 (96.9%) -(IGHD) -IGHJ401 (85.7%), Q120>R (113), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG101, G1m17,1 CH1 K120, CH3 D12, L14, G1v29 CH2 A84.4 (CH1 K120 (218) (122-219), hinge 1-15 (220-234), CH2 G1v29 CH2 N84.4>A (301) (235-344), CH3 D12 (360), L14 (362) (345-449), CHS K2>del (450)) (122-450)], (224-214')-disulfide with kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-1201 (94.7%) -IGKJ401 (91.7%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; dimer (230-230'':233-233'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1 lacking the glutamine synthetase (GS-KO) gene, non-glycosylated Non-Small Cell Lung Carcinoma	Immunitas Therapeutics	P1/2	CC (41)
Interleukin 18 (recombinant human mutein clone ST-067) Non-Small Cell Lung Carcinoma	Simcha IL-18, Inc.	P1/2	CC (41)
jmt203 Non-Small Cell Lung Carcinoma	Shanghai JMT-Bio Inc.	P1/2	CC (41)
Lmv-12 Non-Small Cell Lung Carcinoma	Hunan Province Tumor Hospital	P1/2	CC (41)
Mavrostobart Non-Small Cell Lung Carcinoma	Phanes Therapeutics	P1/2	CC (41)

Showing 76 to 100 of 183 assets

PreviousPage 4 of 8Next